Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma

Christos Emmanouilides, Thomas E. Witzig, Leo I. Gordon, Katie Vo, Gregory A. Wiseman, Ian W. Flinn, Mohamed Darif, Russell J. Schilder, Arturo Molina

Research output: Contribution to journalArticlepeer-review

76 Scopus citations

Fingerprint Dive into the research topics of 'Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma'. Together they form a unique fingerprint.

Medicine & Life Sciences